Novo Nordisk is facing a massive wave of generic competitors to its injectable formulations of GLP-1 agonist semaglutide, used to treat diabetes and obesity, as a key patent in India is due to expire ...
The Supreme Court of the US (SCOTUS) has agreed to hear a patent dispute between Amarin and Hikma that could have implications for the legality of 'skinny labels,' which can help generic drugmakers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results